A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1374-1381

  Reck, M ^a   Kaiser, R ^b   Eschbach, C ^c   Stefanic, M ^b   Love, J ^b   Gatzemeier, U ^a   Stopfer, P ^b   von Pawel, J ^c  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Asklepios Hospital Hamburg Harburg   (Germany)

Author keywords

Angiokinase inhibitor; BIBF 1120; Non small cell lung cancer; Pharmacokinetics; Phase II

Indexed keywords

INTEDANIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RELAPSE; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIMIT OF QUANTITATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION;

EID: 79957452054     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq618     Document Type: Article

References (35)

1. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127-137.
2. Fontanini G, Lucchi M, Vignati S. et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881-886.
3. Macchiarini P, Fontanini G, Dulmet E. et al. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994; 57: 1534-1539.
4. Giatromanolaki A, Koukourakis M, O'Byrne K. et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996; 179: 80-88.
5. Meert AP, Paesmans M, Martin B. et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002; 87: 694-701.
6. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
7. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006; 51: 143-158.
8. Ito H, Oshita F, Kameda Y. et al. Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncol Rep 2002; 9: 119-123.
9. Volm M, Koomagi R, Mattern J. PD-ECGF, bFGF, and VEGF expression in nonsmall cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 1999; 19: 651-655.
10. Koukourakis MI, Giatromanolaki A, O'Byrne KJ. et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 1997; 75: 477-481.
11. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006; 33: 407-420.
12. Hilberg F, Roth GJ, Krssak M. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774-4782.
13. Mross K, Stefanic M, Gmehling D. et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2009; 16: 311-319.
14. Hanna N, Ellis P, Stopfer P. et al. A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer. J Thorac Oncol 2007; 2: S717.
15. Oken MM, Creech RH, Tormey DC. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
16. Therasse P, Arbuck SG, Eisenhauer EA. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
17. Aaronson NK, Ahmedzai S, Bergman B. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
18. Trotti A, Colevas AD, Setser A. et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
19. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69: 1375-1381.
20. Hanna N, Shepherd FA, Fossella FV. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
21. Shepherd FA, Dancey J, Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
22. Socinski MA, Novello S, Brahmer JR. et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 650-656.
23. Gauler TC, Fischer B, Soria J. et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV nonsmall cell lung cancer (NSCLC). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7541.
24. Gatzemeier U, Blumenschein G, Fosella F. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006; 24: 7002.
25. Natale RB, Bodkin D, Govindan R. et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2006; 24: 364S.
26. Natale RB, Thongprasert S, Greco FA. et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009; 27: 15s (suppl; Abstr 8009).
27. Rock EP, Goodman V, Jiang JX. et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12: 107-113.
28. Ratain MJ, Eisen T, Stadler WM. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
29. Kovacs MJ, Reece DE, Marcellus D. et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND.145. Invest New Drugs 2006; 24: 529-535.
30. Zangari M, Anaissie E, Stopeck A. et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10: 88-95.
31. Liu B, Barret T, Choyke P. et al. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24: 17119.
32. Holden SN, Eckhardt SG, Basser R. et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005; 16: 1391-1397.
33. Ryan CJ, Stadler WM, Roth B. et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 2007; 25: 445-451.
34. Camidge DR, Conkling P, Stephenson J, Shapiro D. A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2: S730.
35. Ellis PM, Kaiser R, Zhao Y. et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pre-treated non-small cell lung cancer patients. Clin Cancer Res 2010; 16(10): 2881-2889.